Innovative personalized medicine in gastric cancer: time to move forward. - Wikidata - wikimedia - TriplyDB

Innovative personalized medicine in gastric cancer: time to move forward.

Innovative personalized medicine in gastric cancer: time to move forward.

http://www.wikidata.org/entity/Q38205887

about

MicroRNA-19a mediates gastric carcinoma cell proliferation through the activation of nuclear factor-κB.Cell-Free DNA Provides a Good Representation of the Tumor Genome Despite Its Biased Fragmentation Patterns.Long non-coding RNA UCA1 may be a novel diagnostic and predictive biomarker in plasma for early gastric cancer Novel biomarkers for the identification and targeted therapy of gastric cancer.Drug sensitivity testing platforms for gastric cancer diagnostics.A global burden of gastric cancer: the major impact of China.High expression of EGFR predicts poor survival in patients with resected T3 stage gastric adenocarcinoma and promotes cancer cell survival High STMN1 level is associated with chemo-resistance and poor prognosis in gastric cancer patients.A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer.Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2-Amplified Gastric Cancer Patient-Derived Cell Model.Correlation between MEK signature and Ras gene alteration in advanced gastric cancer.NanoString expression profiling identifies candidate biomarkers of RAD001 response in metastatic gastric cancer.

P2860

Q36089724-3FF3241F-4F5F-4625-BDC1-71483DB8AC87 Q36238197-1462274A-6D45-4613-9AAB-6CBD9482A2F3 Q36375276-45538E74-A1CF-4308-8008-85C26D2137DD Q38556435-2AAEED66-DFDE-4636-828A-D9FCF69A5C61 Q38633116-1056F40B-08F7-440A-B52C-F2FA59769C17 Q38738402-1C6AAB7B-D3FB-418F-AA5C-E382229D6BBA Q38776722-7E53A3F6-D802-4CFC-B1F4-8B1DD62226A3 Q38882319-EFF83997-EA66-4831-A27D-946ECCAF7D0E Q40374075-0F88D631-F2CF-42DE-9DD3-EA6125FED707 Q42269977-5DEDA11B-DFEA-4F75-B365-CD760543E978 Q47145152-47C2C9F5-8AA4-4482-B0B7-A5649BA802F2 Q55077233-153E6628-A82E-4E25-A901-FB901F69FF31

P2860

Innovative personalized medicine in gastric cancer: time to move forward.

http://www.wikidata.org/entity/Q38205887

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Innovative personalized medicine in gastric cancer: time to move forward.

@en

type

label

Innovative personalized medicine in gastric cancer: time to move forward.

@en

prefLabel

Innovative personalized medicine in gastric cancer: time to move forward.

@en

P1433

Q38205887-9D59C73A-51F0-43C0-B02C-8E0D3D8A5D8A

P1476

Q38205887-50F59BBC-C0C2-41AE-823F-57E916A843BD

P2093

Q38205887-3DDB774A-1899-4D7F-B5F6-1032469AC339

Q38205887-3F740D8A-4738-4D2F-B221-EAA205AB2209

Q38205887-D149A0A7-E4F4-474C-A717-502D09031C78

Q38205887-F369D6F0-0AA4-4F23-A98D-B6EA943E36BC

P2860

Q38205887-049A2F6D-0B16-4555-B5C1-E2F0CC425FDE

Q38205887-0792F8F9-FAEA-466A-BFB9-FBED8256DF1C

Q38205887-0DE3A656-1B4F-46D6-9467-8CD4D47EF963

Q38205887-18EC8476-BF18-4E16-9DF6-86151A7571C9

Q38205887-2277B777-E377-4C3C-97BE-E48523203742

Q38205887-2F498BF3-2138-480F-9C31-D88C6641D90E

Q38205887-32A261B9-F415-4C23-A90A-B324D973EB75

Q38205887-34CFE6E1-ABBC-4A33-8894-76589D08CAEA

Q38205887-39C051B7-D5AD-4186-815C-8AA267F59E73

Q38205887-3F16A3CA-53D9-45C1-97AA-A0A7AC582313

P304

Q38205887-3E47835A-C376-445A-9A18-0F1AF2FAD9A4

P31

Q38205887-6C4E40DB-07C8-4BA5-B35E-4C767123CEB4

P356

Q38205887-F2740AC1-822C-442B-9DA1-F710CE2F055D

P433

Q38205887-042C7B0A-9425-46EB-B6DF-2F18E9597E6E

P478

Q38205887-79D2DED9-6157-4C45-B924-2D77D3A85BD9

P577

Q38205887-E46F7730-D103-45C2-BA32-B453DA838FA7

P698

Q38205887-68288039-6447-401E-9075-D6DBDF76068D

P356

P1433

Clinical Genetics

P1476

Innovative personalized medicine in gastric cancer: time to move forward.

@en

P2093

J Lee

http://www.w3.org/2001/XMLSchema#string

K-M Kim

http://www.w3.org/2001/XMLSchema#string

S-H I Ou

http://www.w3.org/2001/XMLSchema#string

W K Kang

http://www.w3.org/2001/XMLSchema#string

P2860

Profiling critical cancer gene mutations in clinical tumor samples

Global cancer statistics

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer.

Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence.

P304

37-43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CGE.12408

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

86

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24749947

http://www.w3.org/2001/XMLSchema#string